Female Sex Hormones Crystalline Powder Mifepristone CAS 68-22-4 Norethisterone
Place of Origin:ShenZhen, China (Mainland)
Type:Antibiotic and Antimicrobial Agents, Antineoplastic Agents, Antiparasitic Agents, Antipyretic Analgesics and NSAIDs, Auxiliaries and Other Medicinal Chemicals
Grade Standard:Medicine Grade
Model Number:Top Grade
Fat Burners:buy Norethisterone
BCAA's-Amino Acid:Norethisterone 50g
Joint Support:cheap Norethisterone
Muscle Building:Norethisterone manufacturer
Norethisterone was the first orally active synthetic progestogen. It was first synthesized in 1951 by Carl Djerassi, Luis E. Miramontes and George Rosenkranz at Syntex in Mexico City.
In addition to its use in contraception Norethisterone was used in high doses in combination with ethinylestradiol until 1973 under the brand name Duogynon and until 1980 under the name Cumorit as a pregnancy test and for the treatment of menstrual disorders.
Schering sold until 1973 in Germany under the brand name Duogynon and until 1980 under the name Cumorit drugs for the treatment of menstrual disorders and as a pregnancy test. Duogynon, taken in early pregnancy , was associated with an accumulation of malformed children in the 1970s. There are supposedly 1000 cases in Germany alone. In 2010, a suspected injured party in broad media interest filed an action for access to the file against the manufacturer Schering, which was dismissed on January 11, 2011 for limitation.  Even with one in November 2011 on behalf of hundreds of victims filed liability claim against Schering failed the plaintiff. The lawsuit was also dismissed for prescription.
In August 2012, the plaintiff accused the Berlin district court of not having followed up references to a presumed influence on research results by employees of the Schering Group. A former Schering employee allegedly admitted to the plaintiff that he had bribed scientists at the beginning of the 1980s in order to make Duogynon appear positive in a brochure. In the room there were payments of 100,000 marks. At that time, the risk of malformations had been known for over a decade and corresponding preparations of competing companies had long since been withdrawn from the market.
The Federal Institute for Drugs and Medical Devices and the Paul Ehrlich Institute published in the Bulletin on Drug Safety in December 2012, that the previously published studies on Duogynon and other estrogen-progestin preparations have no evidence of specific teratogenic effects (teratogenic) in pregnancy Offer. A teratogenic or embryotoxic effect of Duogynon, for any purpose whatsoever, is considered unlikely in the report.
However, on the other hand documents have emerged, which prove that employees of the English Schering headquarters then warned the colleagues in Germany. They recommended removing Duogynon from the market. A former Schering employee is now willing to put these internal doubts in court on record. After the trial files stored in the state archives in Berlin in 2016 were revealed, which showed that even leading Schering employees did not rule out a causal connection between the use of Duogynon and the malformations, the case went on trial again in Germany. In June 2016, a murder complaint was filed on behalf of the mother of an affected child. Murder is a crime that does not expire.
|Product name||CAS number|